Market access webinar

Market access for PD-1 inhibitors: where are we now?

This on-demand webinar shares our thoughts on evaluations for PD-1 inhibitors and assess some of the implications for manufacturers.

Fill in your details to watch this webinar

We respect your privacy. Cookie policy.

The points raised have broad oncology appeal as well as highlighting market access issues which have relevancy for rapidly evolving landscapes.

Discussion points:

  • Key emerging trends on market access
  • How agencies are approaching assessments for melanoma, lung cancer and RCC
  • Specific review of PD-1 testing in health technology assessments
  • Explore the move in the treatment towards combination therapies

Presenters:

Duration: 45 minutes. Available to watch on demand.

Ideal viewing: Global, regional, and affiliate market access and HEOR teams involved in pricing strategy and pricing and reimbursement decisions can benefit from watching this on-demand webinar. Please share this with your colleagues.

Broadcast: 2017

Market access for PD-1 inhibitors: where are we now?

Previous webinars

Driving BioPharma Access in Europe: Insights for Markets Outside of EU5  

Read more >

Positioning for market access success in the evolving landscape of precision medicine

Read more >

Navigating the cell and gene therapy market access landscape

Read more >

Understanding the concept of early scientific advice and its purpose across HTA markets

Read more >

Increase your influence in early pipeline planning: why earlier value assessment of your assets through a payer lens makes a difference.

Read more >

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Read more >

Market access for biotechnology

Read more >

How to build an optimized GVD to populate local HTA/payer templates

Read more >

Recommendations for driving your journey to digital excellence

Read more >

The PRMA Healthcheck®: the future of market access in Asia-Pacific

Read more >

PRMA Healthcheck® for assets in early stages of clinical development

Read more >

The evolution of the PRMA Healthcheck® for US payer archetypes

Read more >

Navigating the updated 2020 ICER value assessment framework

Read more >

Accelerate the time to patient access with the PRMA Navigator®

Read more >

EUnetHTA joint clinical assessments: where have we come from and where are we going?

Read more >

Future proofing for the 2020s market access trends

Read more >

Managed entry agreements: lessons from EU5

Read more >

CAR-T therapy: the future begins to take shape

Read more >

Indication-specific pricing: the obvious solution

Read more >

Payer perspectives on cell and gene therapies: opportunities and challenges

Read more >

Market access considerations for CAR-Ts: insights from ASH

Read more >

Patient-centricity: shaping value generation for HTA and market access

Read more >

Does 1+1 always equal 2? Valuing combinations

Read more >

Clarity or confusion: the role of value frameworks in oncology

Read more >